Oct 30, 2008 by Brian Orelli, PhDWhat's on Deck for AstraZeneca?The drugmaker increases EPS by cutting costs, but it's the next move that'll count the most.
Oct 29, 2008 by Brian Orelli, PhDCredit Crisis Hits DrugmakersWhat happened to being recession-proof?
Oct 27, 2008 by Brian Orelli, PhDHansen Medical Bucks the TrendThere's still growth in the medical-device maker after all.
Oct 24, 2008 by Brian Orelli, PhDLilly's Results Run the GamutThe company's GAAP EPS and adjusted EPS are at polar extremes.
Oct 24, 2008 by Brian Orelli, PhDAffymetrix Has Trouble Turning AroundIt's dirt cheap, but a turnaround isn't imminent.
Oct 23, 2008 by Brian Orelli, PhDGetting Bigger to SurviveAmerican Oriental Bioengineering has no other choice.
Oct 23, 2008 by Brian Orelli, PhDBoston Scientific Should Be ThankfulIts two-year-old acquisition of Guidant saved it in the third quarter.
Oct 23, 2008 by Brian Orelli, PhDGlaxo to Competitors: You're Cheaper Than We AreIt's got cash and it plans to use it.
Oct 22, 2008 by Brian Orelli, PhDBiogen Has Growth in all the Wrong PlacesThe company needs more Tysabri patients.
Oct 22, 2008 by Brian Orelli, PhDWhy Amylin Skipped Some Byetta NumbersWhat a company doesn't point out might be important.
Oct 22, 2008 by Brian Orelli, PhDMerck's a Bloated Garbage Heap of Stale DrugsStay away -- really far away.
Oct 21, 2008 by Brian Orelli, PhDThe World Is Saving PfizerThe company experienced a double-digit decrease in U.S. sales. Ouch.
Oct 21, 2008 by Brian Orelli, PhDNovartis Is Taking the Road Less TraveledDiversification should pay off for this pharma giant.
Oct 21, 2008 by Brian Orelli, PhDSchering Buys Great GrowthAcquiring Organon Biosciences saves the company from a rough quarter.
Oct 20, 2008 by Brian Orelli, PhDFoolish Forecast: Will Pfizer Flounder Through Another Quarter?Views you can use for tomorrow's news.
